MBCproject_0080_T2_RNA
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEME_METABOLISM+0.640
- E2F_TARGETS+0.400
- IL6_JAK_STAT3_SIGNALING+0.350
- ALLOGRAFT_REJECTION+0.330
- G2M_CHECKPOINT+0.330
- INFLAMMATORY_RESPONSE+0.310
- INTERFERON_GAMMA_RESPONSE+0.290
- INTERFERON_ALPHA_RESPONSE+0.260
- COMPLEMENT+0.250
- PI3K_AKT_MTOR_SIGNALING+0.250
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.330
- MYC_TARGETS_V1-0.310
- MYC_TARGETS_V2-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.270
- MYOGENESIS-0.260
- ESTROGEN_RESPONSE_LATE-0.220
- UNFOLDED_PROTEIN_RESPONSE-0.200
- APICAL_JUNCTION-0.170
- NOTCH_SIGNALING-0.170
- P53_PATHWAY-0.170
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BSR_02_0049_A5_S69 | — | D | 0.714 |
| 2 | ERR2208913 | — | — | 0.704 |
| 3 | SET2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.699 |
| 4 | 7d3b4d06-1249-4a85-a66a-387d4e2e2cb2 | — | — | 0.692 |
| 5 | SRR8613787 | — | D | 0.682 |
| 6 | TCGA-E2-A159-01A-11R-A115-07 | — | C | 0.679 |
| 7 | SRR6013581 | — | cohortA1 | 0.676 |
| 8 | MBCproject_0280_T1_RNA | — | E | 0.675 |
| 9 | TCGA-E9-A243-01A-21R-A169-07 | — | D | 0.673 |
| 10 | SRR5088912 | — | — | 0.669 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEME_METABOLISM | 0.640 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.400 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.330 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.310 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.290 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.210 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.140 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.140 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.080 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.050 | Idelalisib | — uncovered |